OBI Pharma Signs Collaboration and License Agreement with Novartis
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered...
TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered...
MYQORZO is the Only Cardiac Myosin Inhibitor with Data in Its U.S. Label Comparing Its Effectiveness to the Beta Blocker...
– ATL-101 achieved robust (~80%) and durable (> 6 months after single administration) HTT lowering in the striatum, the key...
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for...
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI)...
Last patient has completed the final study visit in the Phase 2 trial in older adults with COPD-induced muscle weakness,...
Dick Boer Dick Boer Laurence Debroux Laurence Debroux Todd Brinton Todd Brinton November 16, 2026 Dick Boer, former President and...
PRESS RELEASE Paris, 16 November 2026 Ramsay Santé announces full Board structure to support its next phase of development Frédéric...
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...
Former ADSTILADRIN® global clinical development leader brings extensive uro-oncology expertise as Relmada prepares to initiate the Phase 3 SPECTRUM program...
FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building...
Designation covers daretabart in combination with induction chemotherapy for first-line treatment in paediatric patientsFirst Breakthrough Therapy Designation (BTD) for daretabart,...
Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced...
Approval based on phase III MAJESTY results demonstrating Gazyva/Gazyvaro superiority over tacrolimus in achieving complete remission of proteinuria at two...
Vancouver-Based Supplier Recognized for a Documented 99.79% HPLC Purity Result, Accessible Batch Documentation, and Domestic FulfilmentVancouver, British Columbia, Nov. 16,...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
ROCKVILLE, Md., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated...
NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
- All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival...
Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026NEW YORK and TORONTO, Nov. 15, 2026 (GLOBE...